High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients.
To assess the relationship between antiretroviral drug exposure and lipodystrophy, 69 human immunodeficiency virus type 1-infected patients receiving nelfinavir were investigated cross-sectionally. Lipodystrophy was defined by patients' self-report. Nelfinavir trough concentrations in plasma were significantly related to overall lipodystrophy and peripheral fat wasting scores and appeared to be an independent risk factor for lipodystrophy
Tréluyer
Jean-Marc
JM
Pharmacologie Périnatale et Pédiatrique, Groupe Hospitalier Cochin-Saint Vincent de Paul (AP-HP), Université René Descartes, 75674 Paris Cedex 14, France. jm.treluyer@svp.ap-hop-paris.fr
Morini
Jean-Pierre
JP
Dimet
Jérome
J
Gorin
Isabelle
I
Rey
Elisabeth
E
Deleuze
Jean
J
Ceccaldi
Pierre-François
PF
Escande
Jean-Paul
JP
Pons
Gérard
G
Dupin
Nicolas
N
D001823:Body Composition; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D015497:HIV-1; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D019888:Nelfinavir / Q000009:adverse effects*; D012307:Risk Factors
D017320:HIV Protease Inhibitors; D019888:Nelfinavir